Friday 6 November 2026
Export BAX’s income statement to Excel — free account
Baxter International Inc.
BAX Healthcare Medical Instruments & Supplies
Baxter International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 billion, up 5.72% from fiscal 2024.
- Revenue
- +4.97%
- EPS
- +731.9%
- Free cash flow
- +255.6%
- Total debt
- −9.48%
Quarter to September 2026, against a year earlier
25.57
0.93
−3.51%
Follow BAX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.87 | 0.76 | 0.96 | 1.07 | |
P/FCF ratio |
29.53 | 11.97 | 13.52 | 10.91 | |
P/Operating CF |
16.79 | 40.62 | 38.68 | 22.24 | |
P/B ratio |
1.61 | 1.44 | 1.78 | 1.92 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.54 | 1.42 | 1.60 | 1.64 | |
EV/EBITDA |
11.96 | 11.13 | 12.61 | 12.61 | |
EV/Operating CF |
20.49 | 12.87 | 13.90 | 11.61 | |
EV/FCF |
52.15 | 22.27 | 22.49 | 16.74 | |
Quick Ratio |
1.29 | 1.01 | 1.12 | 0.99 | |
Current Ratio |
2.31 | 1.85 | 1.95 | 1.79 | |
Net Debt/EBITDA |
26.26 | 24.57 | 16.03 | 14.28 | |
Debt/Assets |
47.25% | 47.68% | 47.79% | 44.30% | |
Debt/Equity |
1.55 | 1.57 | 1.53 | 1.33 | |
Asset Turnover |
0.49 | 0.55 | 0.56 | 0.57 | |
Operating CF/Net income |
(0.52) | (14.20) | 2.26 | 1.90 | |
Capex/Depreciation |
(0.14) | (0.58) | (0.49) | (0.46) | |
Interest Coverage |
(12.57) | 1.00 | 3.39 | 3.69 | |
Research and Development Expense of Revenue |
4.24% | 5.15% | 4.36% | 4.20% | |
Selling, General and Administrative Expense of Revenue |
25.59% | 26.95% | 24.83% | 24.53% | |
Intangible Assets out of Total Assets |
0.46 | 0.46 | 0.45 | 0.45 | |
Share Based Compensation of Revenue |
1.24% | 0.37% | 1.11% | 1.01% | |
Graham Net Nets |
(0.72) | (0.81) | (0.60) | (0.49) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(9.68%) | (12.68%) | (9.71%) | (5.88%) | |
Free Cash Flow Yield |
3.39% | 8.36% | 7.39% | 9.16% | |
Revenue per Share |
5.80 | 5.24 | 5.73 | 5.76 | |
Operating CF per Share |
1.14 | 0.41 | 0.55 | 1.08 | |
Capex per Share |
(0.27) | (0.27) | (0.22) | (0.21) | |
Free Cash Flow per Share |
0.87 | 0.15 | 0.33 | 0.87 | |
Cash per Share |
3.83 | 3.92 | 4.16 | 3.82 | |
Shareholders Equity per Share |
11.89 | 11.68 | 11.95 | 12.52 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.89 | 11.68 | 11.95 | 12.52 | |
Free Cash Flow |
444.00 | 76.00 | 169.00 | 448.00 | |
Working Capital |
3,902.00 | 3,154.00 | 3,398.00 | 3,017.00 | |
Capital Expenditures |
(140.00) | (137.00) | (116.00) | (110.00) | |
Net Current Asset Value |
(7,081.00) | (6,983.00) | (6,623.00) | (6,113.00) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.05 | 0.04 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1,770.00 | 1,672.00 | 1,814.50 | 1,780.00 | |
Average Payables |
983.50 | 1,024.50 | 1,014.50 | 988.50 | |
Average Inventory |
2,139.00 | 2,243.00 | 2,321.50 | 2,380.00 | |
Average Assets |
22,918.50 | 20,575.00 | 20,418.50 | 20,240.50 | |
Average Common Equity |
6,563.00 | 6,535.00 | 6,736.00 | 6,844.50 |
Columns are period end dates · fundamentals updated 2 Nov 2026